nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.01.2009 | Preclinical Study

Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis

verfasst von: Mads Thomassen, Qihua Tan, Torben A. Kruse

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer cells exhibit complex karyotypic alterations causing deregulation of numerous genes. Some of these genes are probably causal for cancer formation and local growth whereas others are causal for the various steps of metastasis. In a fraction of tumors deregulation of the same genes might be caused by epigenetic modulations, point mutations or the influence of other genes. We have investigated the relation of gene expression and chromosomal position, using eight datasets including more than 1200 breast tumors, to identify chromosomal regions and candidate genes possibly causal for breast cancer metastasis. By use of “Gene Set Enrichment Analysis” we have ranked chromosomal regions according to their relation to metastasis. Overrepresentation analysis identified regions with increased expression for chromosome 1q41–42, 8q24, 12q14, 16q22, 16q24, 17q12–21.2, 17q21–23, 17q25, 20q11, and 20q13 among metastasizing tumors and reduced gene expression at 1p31–21, 8p22–21, and 14q24. By analysis of genes with extremely imbalanced expression in these regions we identified DIRAS3 at 1p31, PSD3, LPL, EPHX2 at 8p21–22, and FOS at 14q24 as candidate metastasis suppressor genes. Potential metastasis promoting genes includes RECQL4 at 8q24, PRMT7 at 16q22, GINS2 at 16q24, and AURKA at 20q13.

Nur mit Berechtigung zugänglich

Thomassen M, Tan Q, Eiriksdottir F, Bak M, Cold S, Kruse TA (2007) Prediction of metastasis from low-malignant breast cancer by gene expression profiling. Int J Cancer 120:1070–1075PubMedCrossRef

Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF et al (2003) Gene expression predictors of breast cancer outcomes. Lancet 361:1590–1596PubMedCrossRef

Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A et al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100:10393–10398PubMedCrossRef

Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J et al (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262–272PubMedCrossRef

Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671–679PubMed

van de Vijver, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009PubMedCrossRef

Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A et al (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 102:13550–13555PubMedCrossRef

Calza S, Hall P, Auer G, Bjohle J, Klaar S, Kronenwett U et al (2006) Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 8:R34PubMedCrossRef

Tan Q, Thomassen M, Kruse TA (2007) Feature selection for predicting tumor metastases in microarray experiments using paired design. Cancer Inform 2:133–138

10.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545–15550PubMedCrossRef

11.

Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J et al (2002) Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 30:e15PubMedCrossRef

12.

Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N et al (2007) The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest 117:206–217PubMedCrossRef

13.

Ragnarsson G, Eiriksdottir G, Johannsdottir JT, Jonasson JG, Egilsson V, Ingvarsson S: (1999) Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br J Cancer 79:1468–1474PubMedCrossRef

14.

Borg A, Zhang QX, Olsson H, Wenngren E (1992) Chromosome 1 alterations in breast cancer: allelic loss on 1p and 1q is related to lymphogenic metastases and poor prognosis. Genes Chromosomes Cancer 5:311–320PubMedCrossRef

15.

Janssen EA, Baak JP, Guervos MA, van Diest PJ, Jiwa M, Hermsen MA (2003) In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor. J Pathol 201:555–561PubMedCrossRef

16.

Morikawa A, Williams TY, Dirix L, Colpaert C, Goodman M, Lyles RH et al (2005) Allelic imbalances of chromosomes 8p and 18q and their roles in distant relapse of early stage, node-negative breast cancer. Breast Cancer Res 7:R1051–R1057PubMedCrossRef

17.

Isola JJ, Kallioniemi OP, Chu LW, Fuqua SA, Hilsenbeck SG, Osborne CK et al (1995) Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol 147:905–911PubMed

18.

Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H et al (2004) Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64:8534–8540PubMedCrossRef

19.

Karlsson E, Danielsson A, Delle U, Olsson B, Karlsson P, Helou K (2007) Chromosomal changes associated with clinical outcome in lymph node-negative breast cancer. Cancer Genet Cytogenet 172:139–146PubMedCrossRef

20.

Rayburn E, Zhang R, He J, Wang H (2005) MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 5:27–41PubMedCrossRef

21.

Wang ZC, Lin M, Wei LJ, Li C, Miron A, Lodeiro G et al (2004) Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 64:64–71PubMedCrossRef

22.

Martin MD, Fischbach K, Osborne CK, Mohsin SK, Allred DC, O’Connell P (2001) Loss of heterozygosity events impeding breast cancer metastasis contain the MTA1 gene. Cancer Res 61:3578–3580PubMed

23.

Hicks J, Krasnitz A, Lakshmi B, Navin NE, Riggs M, Leibu E et al (2006) Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 16:1465–1479PubMedCrossRef

24.

Hansen LL, Yilmaz M, Overgaard J, Andersen J, Kruse TA (1998) Allelic loss of 16q23.2–24.2 is an independent marker of good prognosis in primary breast cancer. Cancer Res 58:2166–2169PubMed

25.

Wennmalm K, Calza S, Ploner A, Hall P, Bjohle J, Klaar S et al (2007) Gene expression in 16q is associated with survival and differs between Sorlie breast cancer subtypes. Genes Chromosomes Cancer 46:87–97PubMedCrossRef

26.

Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R et al (2006) Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 6:96PubMedCrossRef

27.

Parssinen J, Kuukasjarvi T, Karhu R, Kallioniemi A (2007) High-level amplification at 17q23 leads to coordinated overexpression of multiple adjacent genes in breast cancer. Br J Cancer

28.

Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V et al (2006) Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 6:245PubMedCrossRef

29.

Chin SF, Wang Y, Thorne NP, Teschendorff AE, Pinder SE, Vias M et al (2007) Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. Oncogene 26:1959–1970PubMedCrossRef

30.

Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y et al (1999) NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A 96:214–219PubMedCrossRef

31.

Widschwendter M, Siegmund KD, Muller HM, Fiegl H, Marth C, Muller-Holzner E et al (2004) Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 64:3807–3813PubMedCrossRef

32.

Wang W, Huper G, Guo Y, Murphy SK, Olson JA Jr, Marks JR (2005) Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer. Oncogene 24:2705–2714PubMedCrossRef

33.

Pils D, Horak P, Gleiss A, Sax C, Fabjani G, Moebus VJ et al (2005) Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival. Cancer 104:2417–2429PubMedCrossRef

34.

Heintel D, Kienle D, Shehata M, Krober A, Kroemer E, Schwarzinger I et al (2005) High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia 19:1216–1223PubMedCrossRef

35.

Buffart TE, Coffa J, Hermsen MA, Carvalho B, van dS Jr, Ylstra B et al (2005) DNA copy number changes at 8q11–24 in metastasized colorectal cancer. Cell Oncol 27:57–65PubMed

36.

Narayan G, Bourdon V, Chaganti S, rias-Pulido H, Nandula SV, Rao PH et al (2007) Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer 46:373–384PubMedCrossRef

37.

Turbin DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De LA et al (2006) MDM2 protein expression is a negative prognostic marker in breast carcinoma. Mod Pathol 19:69–74PubMedCrossRef

38.

Milde-Langosch K (2005) The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 41:2449–2461PubMedCrossRef

39.

Kustikova O, Kramerov D, Grigorian M, Berezin V, Bock E, Lukanidin E et al (1998) Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol Cell Biol 18:7095–7105PubMed

40.

Caldeira JR, Prando EC, Quevedo FC, Neto FA, Rainho CA, Rogatto SR (2006) CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer 6:48PubMedCrossRef

41.

Seki T, Akita M, Kamimura Y, Muramatsu S, Araki H, Sugino A (2006) GINS is a DNA polymerase epsilon accessory factor during chromosomal DNA replication in budding yeast. J Biol Chem 281:21422–21432PubMedCrossRef

42.

Ginestier C, Cervera N, Finetti P, Esteyries S, Esterni B, Adelaide J et al (2006) Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res 12:4533–4544PubMedCrossRef

43.

Landen CN Jr, Lin YG, Immaneni A, Deavers MT, Merritt WM, Spannuth WA et al (2007) Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res 13:4098–4104PubMedCrossRef

44.

Royce ME, Xia W, Sahin AA, Katayama H, Johnston DA, Hortobagyi G et al (2004) STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. Cancer 100:12–19PubMedCrossRef

45.

Thomassen M, Tan Q, Eiriksdottir F, Bak M, Cold S, Kruse TA (2007) Comparison of gene sets for expression profiling: prediction of metastasis from low-malignant breast cancer. Clin Cancer Res 13:5355–5360PubMedCrossRef

46.

Kauraniemi P, Kuukasjarvi T, Sauter G, Kallioniemi A (2003) Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. Am J Pathol 163:1979–1984PubMed

Titel: Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis
verfasst von: Mads Thomassen
Qihua Tan
Torben A. Kruse
Publikationsdatum: 01.01.2009
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2009
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-9927-2

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2009

Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC)

TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype

Long-term “protective” effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients

Lymphatic and angiogenic characteristics in breast cancer: morphometric analysis and prognostic implications

Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines

Donor-derived breast cancer in a bone marrow transplantation recipient

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie